Patents by Inventor Ryan Faucette

Ryan Faucette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK
    Publication number: 20210025898
    Abstract: Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.
    Type: Application
    Filed: December 15, 2016
    Publication date: January 28, 2021
    Applicant: Dyax Corp.
    Inventors: Jiang Wu, Guodong Zhang, Daniel J. Sexton, Ryan Faucette, Gul M. Mustafa, Mark Szewc
  • Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
    Patent number: 10870115
    Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: December 22, 2020
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Ryan Faucette
  • METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM
    Publication number: 20190361036
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Application
    Filed: September 15, 2017
    Publication date: November 28, 2019
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • RNA BIOMARKERS FOR HEREDITARY ANGIOEDEMA
    Publication number: 20190241961
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Application
    Filed: September 15, 2017
    Publication date: August 8, 2019
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION
    Publication number: 20190022641
    Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
    Type: Application
    Filed: August 12, 2016
    Publication date: January 24, 2019
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Ryan Faucette
  • IMMUNOASSAY TO DETECT CLEAVED HIGH MOLECULAR WEIGHT KININOGEN
    Publication number: 20180306807
    Abstract: The present disclosure provides immunoassay methods of detecting a cleaved high molecular weight kininogen (HMWK) with high sensitivity and specificity and isolated antibodies that specifically bind cleaved HMWK
    Type: Application
    Filed: October 19, 2016
    Publication date: October 25, 2018
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Ryan Faucette, Janja Cosic
  • PLASMA KALLIKREIN BINDING PROTEINS AND USES THEREOF IN TREATING HEREDITARY ANGIOEDEMA
    Publication number: 20170002094
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Application
    Filed: January 21, 2015
    Publication date: January 5, 2017
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Rayan larrobino, Joe Biedenkapp
  • ASSAYS FOR DETERMINING PLASMA KALLIKREIN SYSTEM BIOMARKERS
    Publication number: 20160252527
    Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
    Type: Application
    Filed: October 17, 2014
    Publication date: September 1, 2016
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
  • EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS
    Publication number: 20150362493
    Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
    Type: Application
    Filed: January 17, 2014
    Publication date: December 17, 2015
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman, Yung Chyung
  • Methods for reducing the mitogenicity of lectin compositions
    Patent number: 8729242
    Abstract: Methods for reducing the T-cell mitogenicity of lectin compositions are provided. In one aspect this is achieved by chemically modifying mitogenic lectin compositions under optimized conditions. Additionally or alternatively, the reduction in T-cell mitogenicity is achieved by removing unmodified subunits chemically modified mixtures. Modified lectin compositions with reduced T-cell mitogenicity are also provided as are uses of the inventive compositions.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: May 20, 2014
    Assignee: Smartcells, Inc.
    Inventors: Thomas M. Lancaster, Wenyi Cai, Ryan Faucette, Matthew Pecukonis, Todd C. Zion
  • METHODS FOR REDUCING THE MITOGENICITY OF LECTIN COMPOSITIONS
    Publication number: 20100130726
    Abstract: Methods for reducing the T-cell mitogenicity of lectin compositions are provided. In one aspect this is achieved by chemically modifying mitogenic lectin compositions under optimized conditions. Additionally or alternatively, the reduction in T-cell mitogenicity is achieved by removing unmodified subunits chemically modified mixtures. Modified lectin compositions with reduced T-cell mitogenicity are also provided as are uses of the inventive compositions.
    Type: Application
    Filed: January 27, 2010
    Publication date: May 27, 2010
    Applicant: SMARTCELLS, INC.
    Inventors: Thomas M. LANCASTER, Wenyi CAI, Ryan FAUCETTE, Matthew PECUKONIS, Todd C. ZION
  • Methods for reducing the mitogenicity of lectin compositions
    Patent number: 7687608
    Abstract: Methods for reducing the T-cell mitogenicity of lectin compositions are provided. In one aspect this is achieved by chemically modifying mitogenic lectin compositions under optimized conditions. Additionally or alternatively, the reduction in T-cell mitogenicity is achieved by removing unmodified subunits chemically modified mixtures. Modified lectin compositions with reduced T-cell mitogenicity are also provided as are uses of the inventive compositions.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: March 30, 2010
    Assignee: SmartCells, Inc.
    Inventors: Thomas M. Lancaster, Wenyi Cai, Ryan Faucette, Matthew Pecukonis, Todd C. Zion
  • Methods for reducing the mitogenicity of lectin compositions
    Publication number: 20070110811
    Abstract: Methods for reducing the T-cell mitogenicity of lectin compositions are provided. In one aspect this is achieved by chemically modifying mitogenic lectin compositions under optimized conditions. Additionally or alternatively, the reduction in T-cell mitogenicity is achieved by removing unmodified subunits chemically modified mixtures. Modified lectin compositions with reduced T-cell mitogenicity are also provided as are uses of the inventive compositions.
    Type: Application
    Filed: October 19, 2006
    Publication date: May 17, 2007
    Inventors: Thomas Lancaster, Wenyi Cai, Ryan Faucette, Matthew Pecukonis, Todd Zion